Merck (MRK) Stock Outlook 2026: Keytruda's Patent Cliff and the Pipeline Race
Merck (MRK) 2026 stock outlook: Keytruda patent cliff preparation ahead of 2028 expiry, subcutaneous formulation strategy, IRA drug pricing negotiation impact, next-generation oncology pipeline depth, dividend growth sustainability, and whether MRK fits in an income or growth portfolio.
MRK Merck US Stocks
